PET and PET/CT for response evaluation in lymphoma: Current practice and developments
- 1 January 2007
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (2), 270-282
- https://doi.org/10.1080/10428190601078118
Abstract
Positron emission tomography (PET) using the radiolabelled glucose analog 2-[18F]fluoro-2-deoxy-d-glucose (FDG) is increasingly used for response assessment in patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). These patients often present with a residual mass after therapy, but only a minority will relapse as most of these masses consist of inactive fibrosis. However, some patients have residual disease after first-line treatment and they can benefit from additional or early salvage therapy. Special interest for early, but accurate, assessment of response is growing accordingly. Conventional radiological techniques cannot differentiate between active tumoural tissue and fibrosis in these masses. In contrast, FDG-PET has the ability to differentiate between viable tumour and fibrosis and has been evaluated as an initial staging tool, for response assessment after completion of therapy and as a prognostic marker early during treatment. In this review, we will focus especially on the value of PET for response assessment.Keywords
This publication has 54 references indexed in Scilit:
- Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?Annals of Oncology, 2005
- Intensity of18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2005
- [18F]3′-Deoxy-3′-Fluorothymidine–PET in NHL Patients: Whole-Body Biodistribution and Imaging of Lymphoma Manifestations—a Pilot StudyCancer Biotherapy & Radiopharmaceuticals, 2004
- Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin’s lymphoma in three randomised EORTC trialsEuropean Journal Of Cancer, 2004
- FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients withde novoHodgkin Lymphoma: A Blinded ComparisonLeukemia & Lymphoma, 2004
- 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non‐Hodgkin's lymphomaBritish Journal of Haematology, 2003
- Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” LymphomaJournal of Clinical Oncology, 2002
- Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphomaBone Marrow Transplantation, 2002
- Magnetic resonance imaging and67ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot studyMagnetic Resonance Materials in Physics, Biology and Medicine, 1996
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995